相关临床试验
4
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1958
进行中（未招募）
3
75.0%
已完成
1
25.0%
暂无批准数据
- Scientists at The Ohio State University engineered extracellular vesicles from red blood cell lipids using microfluidics, creating nanocarriers that evade immune cells and target cancer cells. - The platform packages cargo ranging from genetic material and proteins to whole adeno-associated viruses, with a CD47 peptide protecting carriers from macrophage clearance. - Anti-PD-L1-tagged vesicles showed preferential uptake in PD-L1-positive breast cancer tumors, and encapsulated AAVs were shielded from neutralizing antibodies. - Researchers aim to focus on gene therapy and lung-targeting therapeutics, leveraging a sustainable source of expired red blood cells that would otherwise be discarded.
- The Ohio State University received a $4 million NSF Phase II design grant under the National Quantum Virtual Laboratory program to lead the DQS-CP quantum sensing consortium. - The two-year project aims to engineer a multi-component quantum sensing platform capable of capturing atomic and molecular interactions with sub-atomic precision for biomedical applications. - The sensing architecture uses three integrated layers — target analyte, spin-relay film, and entanglement-assisted quantum readout — to bypass classical resolution barriers. - A national network of academic partners including MIT, University of Chicago, UCSB, and CU Boulder will collaborate, with QuantCAD providing commercialization roadmapping.
- A phase Ib clinical trial demonstrated that adding investigational antibody ianalumab to ibrutinib therapy allowed 17 out of 39 chronic lymphocytic leukemia patients to discontinue daily treatment for 12-24 months. - The combination achieved a 60% overall response rate and 43.6% of patients reached undetectable measurable residual disease, indicating deep remissions that could enable treatment-free intervals. - The therapy showed a favorable safety profile with no dose-limiting toxicities and lower infection rates compared to single-agent ibrutinib, potentially transforming CLL from lifelong to fixed-duration treatment.
- A Phase 3 clinical trial showed epithelium-on corneal cross-linking achieved a full 1-diopter difference between treatment and sham groups, with the treatment group demonstrating half-diopter corneal flattening at 12 months. - The innovative procedure uses specialized oxygen-enriched goggles maintaining over 90% oxygen concentration to enable efficient aerobic cross-linking while preserving the epithelial layer. - The safety profile was exceptional with no serious adverse events reported, eliminating risks associated with traditional epithelium-off approaches including infection, delayed healing, and scarring. - The technique may expand treatment eligibility to patients with thinner corneas or those at risk of surface disease by significantly reducing procedural risks.
- Phase 3 trial demonstrates pirtobrutinib's superior progression-free survival compared to idelalisib or bendamustine plus rituximab in previously treated chronic lymphocytic leukemia patients. - Real-world evidence reveals a significant 10-month extension between progression-free survival and time to next treatment, suggesting enhanced clinical benefits beyond trial results. - Study findings position pirtobrutinib (Jaypirca) as a promising therapeutic option for CLL patients who have received prior BTK inhibitor therapy.
- The 'Young, Empowered & Strong' (YES) study is a multicenter, randomized controlled trial evaluating a mobile app- and web-based intervention for young breast cancer survivors. - YES aims to improve quality of life and address specific concerns and symptoms experienced by adolescent and young adult (AYA) breast cancer patients. - The intervention utilizes electronic patient-reported outcome systems (ePROs) to provide tailored education and resources based on individual needs. - The study will assess the efficacy of YES at 6 months and sustainability at 9 months, with potential for broad application to AYA survivors of other cancers.
- The Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network, launched under the Cancer Moonshot Initiative, is working to enhance patient involvement in cancer research through five NCI-funded centers. - Key priorities include tailoring educational materials, measuring engagement effectiveness, and developing strategies to return genomic data to participants, with special focus on rare and understudied cancers. - Despite progress, significant challenges remain in streamlining consent processes, facilitating health data sharing, and improving electronic health record interoperability across institutions.
• AstraZeneca and Moffitt Cancer Center are collaborating to accelerate cell therapy development, focusing on CAR T and TCR T therapies for solid tumors. • SWOG Cancer Research Network developed a risk prediction model to identify cancer patients at high risk for emergency room visits during clinical trials. • A national clinical trial is launched by UC San Francisco to repurpose existing drugs for treating traumatic brain injury (TBI), addressing a critical unmet need. • The Ohio State University initiates clinical trials for HOSU-53, a novel DHODH inhibitor, in partnership with Jabez Biosciences, targeting cancer metabolism.
- The AVMA Veterinary Clinical Trials Registry lists studies for animal health, connecting researchers with veterinarians and owners. - North Carolina State University is exploring a novel treatment approach for oral cancer in cats. - Several studies are investigating canine cancers, including hemangiosarcoma, osteosarcoma, and mast cell tumors, with innovative therapies. - Research is underway to assess treatments for canine cognitive dysfunction and degenerative myelopathy, mirroring human neurological conditions.
- The USDA has granted conditional license for Elanco's Canine Parvovirus Monoclonal Antibody, marking the first approved therapeutic solution to treat canine parvovirus. - In efficacy studies, all 28 treated puppies survived with significantly faster recovery times for vomiting, inappetence, and lethargy compared to traditional supportive care. - The single intravenous dose treatment could reduce hospitalization costs and make parvovirus treatment more accessible to pet owners who previously couldn't afford intensive care. - This breakthrough represents the first monoclonal antibody treatment for Elanco and addresses a critical unmet need in veterinary medicine for a disease with over 90% fatality rate if untreated.
